Novel Agents Increasingly Individualize CLL Care
Read More >>
June Provides Insight Into Managing AEs From CAR T-Cell Therapies
Read More >>
View Free CME from PER >>
FDA Approves Ixazomib for Relapsed Multiple Myeloma
Goy on Going Beyond R-CHOP in Large-Cell Lymphoma
Novel Agents Offer Promise in CLL, But Challenges Remain
Positive Interim Analysis Halts Phase III Idelalisib CLL Study
FDA Approves Daratumumab for Pretreated Multiple Myeloma
Label Update Sought for Ibrutinib in CLL
How Anderson Transformed Multiple Myeloma Care
View More >>
- A Network of Your Peers
View more >>
Dr. Jennifer Brown on Duvelisib in CLL
Treatments for Relapsed Mantle Cell Lymphoma
Dr. Sundar Jagannath on Significant Studies in Multiple Myeloma
Ongoing Role of Transplant in Chronic Lymphocytic Leukemia
Emerging Concepts in Multiple Myeloma
Morie A. Gertz, MD; Heather J. Landau, MD; Jatin J. Shah, MD; and Rafael Fonseca, MD, comment on unmet needs in the treatment of multiple myeloma.
Diagnostic and Response Criteria in Multiple Myeloma
Kenneth Anderson, MD, remarks on the impact of changing treatment eligibility and response criteria in multiple myeloma.
Highlights from the 2014 ASH Annual Meeting
Laura Jones recaps major findings and experts discuss ruxolitinib as a treatment for patients with polycythemia vera.
Treatment and Management
of Acute Leukemia
Moderated by Leonard S. Sender, MD, this panel discussion focuses on therapies for different subgroups of acute lymphocytic leukemia, with input from Dan Douer, MD, Jeffrey Lancet, MD, Mark R. Litzow, MD, and Raoul Tibes, MD, PhD.
Most Popular Right Now
American Journal of Managed Care
Oncology Nursing News
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
Terms & Conditions
666 Plainsboro Road
Plainsboro, NJ 08536
Copyright OncLive 2006-2015
Intellisphere, LLC. All Rights Reserved.